Develops next-generation cancer therapies by targeting specific molecular pathways, such as CYP11A1 and EP4, to inhibit tumor growth and improve treatment efficacy. Its clinical-stage candidates, including INV-9956 and INV-1120, are designed to provide measurable clinical benefits in combination with existing therapies, addressing unmet needs in oncology.
Funding
Funding not disclosed
Founders
Product
Problem
Many cancers develop resistance to existing treatments, and some cancers lack effective therapies altogether. Traditional approaches may not precisely target the molecular mechanisms driving tumor growth, leading to off-target effects and limited efficacy. There remains a need for novel cancer therapies that can overcome resistance and provide measurable clinical benefits, especially when used in combination with current treatments.
Solution
Iova Biosciences is developing next-generation cancer therapies by targeting specific molecular pathways critical for tumor growth and survival. Their approach focuses on inhibiting key enzymes and receptors, such as CYP11A1 and EP4, to disrupt tumor proliferation and modulate the tumor microenvironment. The company's clinical-stage candidates, including INV-9956 (a CYP11A1 inhibitor) and INV-1120 (an EP4 antagonist), are designed to be used in combination with existing therapies to enhance efficacy and address unmet needs in oncology. By precisely targeting these pathways, Iova aims to provide measurable clinical benefits and improve outcomes for patients with various types of cancer. Clinical trials are underway to evaluate the safety and efficacy of these novel therapies.
Target Audience
The primary target audience includes patients with cancers that have developed resistance to existing therapies or lack effective treatment options, as well as oncologists and clinical researchers seeking novel therapeutic strategies.
Features
- INV-9956: A novel CYP11A1 inhibitor in clinical development.
- INV-1120: An EP4 antagonist being evaluated in clinical trials in combination with other therapies such as Keytruda.
- Focus on combination therapies to enhance efficacy of existing treatments.
- Targeting of specific molecular pathways (CYP11A1, EP4) to inhibit tumor growth.